Saw palmetto is a berry extract used for urinary symptoms of prostate enlargement. Early small trials suggested benefit; the two largest and best-designed trials — STEP (2006) and the NIH-funded CAMUS trial (2011), which tested up to three times the usual dose for 72 weeks — found it no better than placebo. The 2023 Cochrane review pooled 27 trials and found an average symptom-score improvement below the threshold a man can notice. A specific hexane extract sold as a medicine in Europe has somewhat better results in its own trials. Saw palmetto is safe at 320 mg a day and does not affect PSA. Evidence for hair loss is weak.
What saw palmetto is
Saw palmetto (Serenoa repens) is a small palm native to the south-eastern United States. Its berries have been used for urinary complaints since the nineteenth century, and extracts of the berry — rich in fatty acids and plant sterols including beta-sitosterol — became one of the most widely used treatments for enlarged prostate symptoms in Europe, where they are sold as medicines, and one of the top-selling supplements in the United States.
How it is supposed to work
Laboratory studies suggest saw palmetto extracts weakly inhibit 5-alpha reductase (the enzyme that makes DHT, which drives prostate growth), reduce inflammation, and have effects on smooth muscle similar to alpha-blockers. None of these effects has been demonstrated to a clinically meaningful degree in men.
What the trials show
The history runs in two phases.
Before 2006, dozens of small, short trials — many lacking proper blinding or placebo — reported that saw palmetto improved urinary symptoms and flow, and early meta-analyses concluded it worked about as well as finasteride.
From 2006, two large, rigorous trials tested that conclusion:
- STEP (2006, New England Journal of Medicine): 225 men with moderate to severe symptoms took 160 mg twice daily of a standardized extract or placebo for a year. No difference in symptom score, flow rate, residual volume, prostate size or quality of life.
- CAMUS (2011, JAMA), funded by the NIH: 369 men took saw palmetto escalating from 320 mg to 960 mg per day — three times the usual dose — or placebo for 72 weeks. Symptom scores improved by 2.2 points on saw palmetto and 3.0 on placebo. No secondary outcome differed, including PSA, flow, residual volume, sexual function and sleep.
The 2023 Cochrane review pooled 27 randomized trials (4,656 men) and found an average improvement in symptom score of about 0.9 points versus placebo, rated high certainty — well below the 3-point change considered noticeable to a patient — and no effect on flow rate or prostate size.
The extract argument
Defenders of saw palmetto point out that "saw palmetto" is not one product. Extracts differ in solvent (hexane, ethanol, supercritical CO₂) and in fatty acid content, and the hexane-extracted lipidosterolic extract sold as Permixon in Europe has its own body of trials showing modest symptom improvement comparable to tamsulosin in some. European urology guidelines give this specific extract a weak recommendation. The counter-argument is that CAMUS used a well-characterized extract at high dose and found nothing, and that the Permixon trials were mostly industry-sponsored.
For a buyer, the practical point is that the extract in most over-the-counter products has not been shown to work, and that products vary too much to assume one is like another.
Evidence by use
| Use | Rating | What the trials show |
|---|---|---|
| Urinary symptoms of BPH (typical OTC extracts) | Mixed, leaning negative | Largest trials negative; pooled effect below clinical significance. |
| Urinary symptoms of BPH (hexane lipidosterolic extract) | Limited | Modest benefit in mostly sponsored European trials. |
| Prostate size | Insufficient | No reduction shown. |
| Male pattern hair loss | Limited | A few small trials suggest slowed loss, far weaker than finasteride or minoxidil. |
| Chronic prostatitis | Insufficient | One small trial negative. |
| Testosterone / libido | Insufficient | No supporting trials. |
Doses studied
320 mg per day of a lipidosterolic extract (standardized to 85–95% fatty acids and sterols), usually as 160 mg twice daily. CAMUS tested up to 960 mg with no added effect. Whole-berry powders and teas contain far less active material and were not what trials tested.
Safety
Saw palmetto is well tolerated. Side effects are mild and infrequent: stomach upset, headache, and occasionally reduced libido. The CAMUS safety analysis found no meaningful difference from placebo at up to 960 mg. It does not affect PSA, so it does not mask cancer detection the way finasteride can. Isolated reports of liver or pancreas problems and of bleeding during surgery exist; it is sensible to stop it two weeks before an operation. It should not be used by women who are pregnant, and has no role in children.
Where it appears in supplements
Saw palmetto is the anchor ingredient of almost every prostate supplement, often combined with beta-sitosterol, pygeum, nettle root, zinc, lycopene and pumpkin seed. Labels rarely state the extract type or fatty acid content, and "saw palmetto berry powder 500 mg" is not equivalent to 320 mg of standardized extract. See prostate supplement research.
Bottom line
For most men buying it, saw palmetto is a safe way to spend money on a modest placebo effect. Men with bothersome urinary symptoms have treatments that work — alpha-blockers within days, 5-alpha reductase inhibitors over months — and a doctor who can rule out the other causes of a weak stream. The question Does saw palmetto work for an enlarged prostate? gives the shorter version.
Frequently asked questions
Does saw palmetto shrink the prostate?
No. Trials measuring prostate volume have not shown a reduction. Finasteride and dutasteride do shrink the gland; saw palmetto does not.
Does saw palmetto lower PSA?
No. In the CAMUS trial PSA was unchanged, which is one respect in which it differs from finasteride. A rising PSA in a man taking saw palmetto is a real rise.
Is the European extract different?
The hexane-extracted lipidosterolic product sold as Permixon is standardized and regulated as a medicine, and its trials show modest benefit; European urology guidelines give it a weak recommendation. Most products sold in the US, UK, Canada and Australia are not that extract, and their composition varies widely.
Can saw palmetto be taken with tamsulosin or finasteride?
No dangerous interaction is known. It is unlikely to add benefit, and a man on effective treatment has little reason to add it.
References
- National Center for Complementary and Integrative Health. Saw Palmetto: Usefulness and Safety (2024). https://www.nccih.nih.gov/health/saw-palmetto
- JAMA. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial (CAMUS) (2011). PubMed PMID 21954478. https://pubmed.ncbi.nlm.nih.gov/21954478/
- NIDDK. Prostate Enlargement (Benign Prostatic Hyperplasia) (2024). https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia
This page discusses supplement ingredients or categories. It may mention a commercial product, with disclosure. It is general health information, not personal medical advice. Read our editorial policy and medical review policy.